The detection of macroprolactin by precipitation and ultrafiltration methods

Endokrynologia Polska

Volumn 62, Issue 6, 2011, Pages 529-536

  Beda Maluga, Karolina ^a   Pisarek, Hanna ^a   Komorowski, Jan ^a   Pawlikowski, Marek ^a   Świȩtosławski, Jacek ^a   Winczyk, Katarzyna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Hyperprolactinaemia; Macroprolactin; Polyethylene glycol; Precipitation; Prolactin; Ultrafiltration

Indexed keywords

MACROGOL; MACROPROLACTIN; PROLACTIN; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; IMMUNOASSAY; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PRECIPITATION; ULTRAFILTRATION;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; FEMALE; FRACTIONAL PRECIPITATION; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PROLACTIN; PROLACTINOMA; REPRODUCIBILITY OF RESULTS; ULTRAFILTRATION; YOUNG ADULT;

EID: 84555189353     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Suh HK, Frantz AG. Size heterogeneity of human prolactin in plasma and pituitary extracts. J Clin Endocrinol Metab 1974; 39: 928-935.
2. Rogol AD, Rosen SW. Prolactin of apparent large molecular size: the major immunoactive prolactin component in plasma of a patient with a pituitary tumor. J Clin Endocrinol Metab 1974; 38: 714-717.
3. Whittaker PG, Wilcox T, Lind T. Maintained fertility in a patient with hyperprolactinemia due to big, big prolactin. J Clin Endocrinol Metab 1981; 53: 863-866. (Pubitemid 13238674)
4. Leite V, Cosby H, Sobrihno LG et al. Characterization of big, big prolactin in patients with hyperprolactinaemia. Clin Endocrin 1992; 37: 365-372.
5. Carlson HE, Markoff E, Lee DW. On the nature of serum prolactin in two patients with macroprolactinemia. Fertil Steril 1992; 58: 78-87.
6. Cavaco B, Leite V, Amparo Santos M et al. Some forms of big, big prolactin behave as a complex of monomelic prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. Clin Endocrinol Metab 1995; 80: 2342-2346.
7. Hattori N. The frequency of macroprolactinemia in pregnant women and the heterogeneity of its etiologies. J Clin Endocrinol Metab 1996; 81:586-590 (Pubitemid 26055668)
8. Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab 1997; 82: 3107-3110. (Pubitemid 27385683)
9. Hattori N. Macroprolactinemia: a new cause of hyperprolactinemia. J Pharmacol Sci 2003; 92: 171-177. (Pubitemid 36992303)
10. Hattori N, Nakayama Y, Kitagawa K et al. Development of anti-PRL (prolactin) autoantibodies by homologous PRL in rats: a model for macroprolactinemia. Endocrinology 2007; 148: 2465-2470 (Pubitemid 46997039)
11. Hattori N, Nakayama Y, Kitagawa K et al. Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. J Endocrinol 2006; 190: 287-293. (Pubitemid 44288366)
12. Hattori N, Nakayama Y, Kitagawa K et al. Anti-prolactin (PRL) autoantibodies suppress PRL bioactivity in patients with macroprolactinaemia. Clin Endocrinol 2008; 68: 72-76. (Pubitemid 350243484)
13. Leslie H, Courtney CH, Bell PM et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 2001: 86; 2743-2746. (Pubitemid 32545732)
14. Vallette-Kasic S, Morange-Ramos I, Selim A et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002; 87: 581-588. (Pubitemid 34158222)
15. Alfonso A, Rieniets KI, Vigersky RA. Incidence and clinical significance of elevated macroprolactin levels in patients with hyperprolactinemia. Endocrinol Pract 2006; 12: 275-280.
16. Beda K, Winczyk K. Makroprolaktyna - wystȩpowanie, metody diagnostyczne i znaczenie kliniczne. FML 2009; 36: 87-110.
17. Jeske W. The main reasons behind variability in detection of prolactin and causes of true or apparent discordance with clinical state. Pol J Endocrinol 2008; 59: 30-32. (Pubitemid 351547475)
18. Olukoga O, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol 1999; 51: 119-126. (Pubitemid 29339545)
19. Fahie-Wilson MN, Ahlquist JA. Hyperprolactinaemia due to macroprolactins: some progress but still a problem. Clin Endocrinol 2003; 58: 683-685. (Pubitemid 36702725)
20. Sadideen H, Swaminathan R. Macroprolactin: what is it and what is its importance? Int J Clin Pract 2006; 60: 457-461.
21. Kavanagh L, McKenna TJ, Fahie-Wilson MN et al. Specificity and clinical utility of methods for the detection of macroprolactin. Clin Chem 2006; 52: 1366-1372. (Pubitemid 43956029)
22. Beltran L, Fahie-Wilson MN, McKenna TJ et al. Serum total prolactin and monomelic prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. Clin Chem 2008; 54: 1673-1681.
23. Prazeres S, Amparo Santos M, Ferreira HG et al. A practical method for the detection of macroprolactinaemia using ultrafiltration. Clin Endocrinol 2003; 58: 686-690. (Pubitemid 36702726)
24. Quinn AM, Rubinas TC, Garbincius CJ et al. Determination of ultrafilterable prolactin elimination of macroprolactin interference with a monomelic prolactin-selective sample pretreatment. Arch Pathol Lab Med 2006; 130: 1807-1812. (Pubitemid 44906957)
25. Landberg E, Wahlberg J, Rydén I et al. Detection of molecular variants of prolactin in human serum, evaluation of a method based on ultrafiltration. Clinica Chimica Acta 2007; 376: 220-225. (Pubitemid 44881004)
26. Germano L, Mormile A, Filtri L et al. Evaluation of polyethylene glycol precipitation as screening test for macroprolactinemia using Architect immunoanalyser. Immuno-analyse & Biologie Spécialisée 2005; 20: 402-407. (Pubitemid 41796963)
27. Kavanagh-Wright L, Smith TP, Gibney J et al. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clin Endocrinol 2009; 70: 599-605.
28. Bjøro T, Mørkrid L, Wergeland R et al. Frequency of hyperprolactinaemia due to large molecular weight prolactin (150-170 kD PRL). Scand J Clin Lab Invest 1995; 55: 139-147.
29. Miyai K, Ichihara K, Kondo et al. Asymptomatic hyperprolactinaemia and prolactinoma in the general population: mass screening by paired assays of serum prolactin. Clin Endocrinol 1986; 25: 549-554. (Pubitemid 16008964)
30. Fahie-Wilson MN, John R, Ellis AR. Macroprolactin; high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005; 42: 175-192. (Pubitemid 40694957)
31. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 2005; 90: 3927-3932. (Pubitemid 41058153)
32. McKenna TJ, Smith T. Hyperprolactinemia due to macroprolactin: a commonly unrecognized phenomenon causing misdiagnosis and mismanagement. The Endocrinologist 2008; 18: 249-254.
33. Elin RJ. College of American Pathologists special ligands participants summary report. 2001: 7.
34. Klee G. College of American Pathologists special ligands participants summary report. 2007: 11.
35. Sapin R, Kertesz G. Macroprolactin detection by precipitation with Protein A - Sepharose: a rapid screening method compared with polyethylene glycol precipitation. Clin Chem 2003; 49: 502-504.
36. Smith TP, Suliman AM, Fahie-Wilson MN et al. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 2002; 87: 5410-5415. (Pubitemid 36034335)
37. Jeske W, Zdunowski P, Bartoszewicz Z et al. Large molecular weight prolactin in patients with hyperprolactinaemia. Pol J Endocrinol 2000; 51: 237-248.
38. Kowalska A, Piwowar M, Szymonek M, et al. Macroprolactinaemia - a clinical problem. Pol J Endocrinol 2007; 58: 559-560.
39. Suliman AM, Smith TP, Gibney J et al. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin Chem 2003; 49: 1504-1509. (Pubitemid 37011739)
40. Zacur HA, Foster GV. Hyperprolactinemia and polycystic ovary syndrome. Semin Reprod Endocrinol 1992; 10: 236-242.
41. Isik AZ, Gulekli B, Zorlu CG et al. Endocrinological and clinical analysis of hyperprolactinemic patients with and without ultrasonically diagnosed polycystic ovarian changes. Gynecol Obstet Invest 1997; 43: 183-185. (Pubitemid 27165998)
42. Bracero N, Zacur HA. Polycystic ovary syndrome and hyperprolactinemia. Obstet Gynecol Clin North Am 2001; 28: 77-84. (Pubitemid 32242541)
43. Cortet-Rudellia C, Sapin R, Bonneville JF, Brued T. Etiological diagnosis of hyperprolactinemia. Annales d'Endocrinologie 2007; 68: 98-105.
44. Kostrzak A, Warenik-Szymankiewicz A, Meczekalski B. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders. Gynecol Endocrinol 2009; 25: 799-806.
45. Escobar-Morreale HF. Macroprolactinemia in women presenting with hyperandrogenic symptoms: implications for the management of polycystic ovary syndrome. Fertil Steril 2004; 82: 1697-1699. (Pubitemid 39611409)
46. Filho RB, Domingues L, Naves L, Ferraz E et al. Polycystic ovary syndrome and hyperprolactinemia are distinct entities. Gynecol Endocrinol 2007; 23: 267-272. (Pubitemid 46897698)